Scintilate's Musings

Although the cannabinoids THC and CBD are the only two cannabinoids required to be disclosed by the Licensed Producers under Canada's marijuana legislation, some dispensaries in the US also only disclose these two cannabinoids in their strains, choosing to ignore the following cannabinoids that have a greater presence over CBD in Indica strains:  Cannabigerol (CBG)  - the link for this cannabinoid is for a patent application filed by GW Pharmaceuticals in treating depression and other mood disorders.  CBG for a number of diseases  - the diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis...

In organic chemistry, a method of separating the compounds in a medicinal plant involves a type of chromatography. The most common types of chromatography used includes gas chromatography (GC), high performance liquid chromatography (HPLC) and thin layer chromatography (TLC).  The United Nations Office on Drugs and Crime (UNODC) , since inception, recommended using Gas Chromatography in determining drug-type marijuana from fiber-type marijuana along with using a ratio of only two cannabinoids - THC and CBD.  They have determined that a ratio of greater than one means drug-type and less than one indicates fiber or hemp type. Chromatogram using GC The problem with gas chromatography is in its lack of ability in separating the cannabinoids cannabichromene - CBC and cannabidiol - CBD.  In most Indica strains tested using Thin Layer Chromatography, there was either no cannabidiol present or there was only trace amounts relative to CBG - cannabige...